Akebia Therapeutics Outperforms Medical Peers with 104.2% YTD Return

Akebia Therapeutics (AKBA) is outperforming its Medical peers this year, with a 104.2% return compared to the sector's -5.7% average. The company has a Zacks Rank of #1 (Strong Buy) and a Zacks Consensus Estimate for full-year earnings that has moved 65.4% higher within the past quarter. AKBA is a member of the Medical - Drugs industry, which has gained 4.1% this year, and is outperforming the Medical sector as a whole.

Akebia Therapeutics (AKBA) has demonstrated exceptional performance in the Medical sector this year, with a year-to-date return of 104.2% compared to the sector's average return of -5.7% [1]. The company's impressive growth is reflected in its Zacks Rank of #1 (Strong Buy), indicating a robust earnings outlook and positive analyst sentiment. Over the past quarter, the Zacks Consensus Estimate for AKBA's full-year earnings has improved by 65.4% [1].

AKBA is a member of the Medical - Drugs industry, which has seen a year-to-date gain of 4.1% [1]. This industry's performance is significantly outperformed by AKBA, highlighting the company's strong position within its sector. The Medical sector as a whole has also seen a year-to-date return of -5.7%, underscoring AKBA's outperformance [1].

Another notable Medical stock that has outperformed the sector this year is ResMed (RMD), which has returned 10.2% year-to-date. ResMed is currently ranked #2 (Buy) by Zacks and has seen its consensus EPS estimate for the current year increase by 1.4% over the past three months [1]. However, AKBA's performance remains more impressive, with a higher return and a more favorable Zacks Rank.

Investors interested in Medical stocks should continue to monitor Akebia Therapeutics and ResMed. These stocks have shown promising performance and are likely to maintain their solid track record in the coming months.

References:
[1] https://www.nasdaq.com/articles/akebia-therapeutics-akba-stock-outpacing-its-medical-peers-year